GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...

These vaccines-Arexvy by GSK and Abrysvo by Pfizer—are the first for RSV. The new vaccines come with common vaccine side effects including swelling or pain at the injection site, fever, and headache, ...

Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in ...